Skip to main content

Table 1 Demographics (n = 89)

From: Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival

Variable

Number (%)*

Median age at perforation in years (range)

62 (26, 85)

Gender

 Male

28 (31)

 Female

61 (69)

Cancer

 Colorectal

42 (47)

 Ovarian

22 (25)

 Brain

8 (9)

 Lung

4 (4)

 Breast

2 (2)

 Cervical

2 (2)

 Other

9 (10)

Systemic therapy at perforation

 Only first-line

23 (26)

 Beyond first-line

66 (74)

On corticosteroids at perforation

 Yes

23 (26)

 No or unknown

66 (74)

  1. *Numbers refer to number of patients and parentheses refer to percentages unless otherwise specified